Open AccessPrevalence of COVID‐19 vaccine reactogenicity among Bangladeshi physicians
Author(s) -
Majumder Md. Anwarul Azim,
Lutfor Afzalunnessa Binte,
Rabbi Ahbab Mohammad Fazle,
Alam A. B. M. Muksudul,
Rahman Mizanur,
Saha Narayan,
Campbell Michael H.,
Haque Mainul,
Nessa Kamrun,
Khondoker Mohib Ullah,
Das Tapas Ranjan,
Rahman Sayeeda,
Jahan Fauzia,
Mashreky Saidur Rahman,
Wahab Abrar,
Siddiqui Md. Tosaddeque Hossain,
HinksonLacorbiniere Karisha,
Ivy Roksana,
Islam Rezaul,
Haider Yusuf,
Omar Eliza,
Ahmed S. M. Moslehuddin,
Reza A. M. Selim,
Daud A. K. M.,
Choudhury Muiz Uddin Ahmed,
Hossain Md. Abed,
Pappu Abdul Matin,
Jahan Nusrat,
Razzaque Mohammed S.
Publication year - 2022
Publication title -
faseb bioadvances
Language(s) - English
Resource type - Journals
ISSN - 2573-9832
DOI - 10.1096/fba.2021-00158
Subject(s) - reactogenicity , medicine , adverse effect , vaccination , asthma , covid-19 , cross sectional study , logistic regression , pandemic , pediatrics , emergency medicine , immunology , immunization , disease , pathology , infectious disease (medical specialty) , antigen
Increased COVID‐19 vaccine hesitancy presents a major hurdle in global efforts to contain the COVID‐19 pandemic. This study was designed to estimate the prevalence of adverse events after the first dose of the Covishield (AstraZeneca) vaccine among physicians in Bangladesh. A cross‐sectional study was conducted using an online questionnaire for physicians ( n = 916) in Bangladesh. Physicians who received at least one dose of the COVID‐19 vaccine were included. The study was carried out from April 12 to May 31, 2021. More than 58% of respondents ( n = 533) reported one or more adverse events. Soreness of the injected arm (71.9%), tiredness (56.1%), fever (54.4%), soreness of muscles (48.4%), headache (41.5%) and sleeping more than usual (26.8%) were the most commonly reported adverse events. Most vaccine‐related reactogenicities were reported by the younger cohorts (<45 years). The majority of respondents reported severity of reactogenicity as “mild,” experienced on the day of vaccination, and lasting for 1–3 days. The most common reactogenicity was pain at the injection site; the second most common was tiredness. Almost half (49.2%) of the physicians took acetaminophen (paracetamol) to minimize the effects of vaccine reactogenicity. Multivariate logistic regression analyses showed that physicians with diabetes and hypertension (OR = 2.729 95% CI: 1.282–5.089) and asthma with other comorbidities (OR = 1.885 95% CI: 1.001–3.551) had a significantly higher risk of vaccine‐related reactogenicities than physicians without comorbidities. Further safety studies with larger cohorts are required to monitor vaccine safety and provide assurance to potential vaccine recipients.